系统性硬化症中部分抗拓扑异构酶1自身抗体及其B细胞受体优先识别拓扑异构酶1-DNA复合物
该研究从系统性硬化症(SSc)患者来源的TOP1反应性B细胞生成抗TOP1单克隆抗体(ATA mAbs)和表达ATA的B细胞系,发现TOP1与DNA结合差异化影响ATA对TOP1的识别;一部分ATA mAbs对TOP1-DNA切割复合物(TOP1cc)结合增强,这类「TOP1cc增强型ATA」在ATA+患者中可见,与ATA水平和间质性肺病相关,可影响TOP1酶功能并增强促炎细胞因子产生。
要点
- 部分抗TOP1自身抗体优先识别TOP1-DNA复合物,提示ATA B细胞应答存在异质性。
- TOP1cc增强型ATA与ATA水平及间质性肺病相关。
- TOP1cc增强型ATA可影响TOP1酶功能并增强单核细胞促炎因子产生。
核心结论
- ATA对DNA结合后TOP1的识别存在差异,提示ATA B细胞应答异质性,可能影响重症SSc的疾病相关过程。
研究设计与样本
- 从患者来源的TOP1反应性B细胞生成ATA单克隆抗体和表达ATA的B细胞系。
- 用酶联免疫吸附试验和质谱光度法测定单克隆及多克隆ATA对TOP1和TOP1cc的反应性。
- 在单核细胞THP-1细胞和原代单核细胞上评估ATA mAbs与TOP1/TOP1cc复合物的免疫刺激特性。
- 在表达ATA的B细胞上测试TOP1-DNA复合物的刺激效应。
主要发现
- TOP1-DNA结合差异化影响ATA mAbs对TOP1的识别,部分ATA mAbs对TOP1cc结合增强,另一些对TOP1和TOP1cc识别程度相似。
- TOP1cc增强型ATA在ATA+患者中可见,并与ATA水平和间质性肺病相关。
- TOP1cc增强型ATA影响TOP1酶功能,与TOP1cc复合时增加THP-1细胞和原代单核细胞的促炎细胞因子产生。
- 表达TOP1cc增强型ATA的B细胞对TOP1-DNA复合物刺激反应强烈,而表达常规ATA的B细胞未观察到叠加效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systemic sclerosis (SSc) is a deleterious disease. Its clinical management is complicated by strong interpatient heterogeneity. Progressive organ fibrosis is linked to autoantibodies against topoisomerase 1 (TOP1). Here, we hypothesised that the interaction between anti-TOP1 autoantibodies (ATAs) and TOP1 could influence SSc pathogenesis. TOP1 is a DNA-binding enzyme. Therefore, we studied the effects and functional consequences of TOP1-DNA binding on ATA recognition. METHODS: ATA monoclonal antibodies (ATA mAbs) and ATA-expressing B cell lines were generated from patient-derived TOP1-reactive B cells. Reactivity of monoclonal and polyclonal ATAs towards TOP1 and TOP1-DNA cleavage complexes (TOP1cc) was determined by enzyme-linked immunosorbent assay and mass photometry. Immunostimulatory properties of ATA mAbs in complex with TOP1/TOP1cc were assessed on monocytic THP-1 cells and primary monocytes. The stimulatory effects of TOP1-DNA complexes were tested on ATA-expressing B cells. RESULTS: TOP1-DNA binding differentially affected TOP1 recognition by ATA mAbs. A subset of ATA mAbs showed enhanced binding to TOP1cc, whereas others recognised TOP1 and TOP1cc to a similar extent. ATAs with enhanced TOP1cc recognition were observed in ATA+ patients and correlated with ATA levels and interstitial lung disease. These 'TOP1cc-enhanced ATAs' affected the enzymatic function of TOP1 and, in complex with TOP1cc, increased proinflammatory cytokine production by THP-1 cells and primary monocytes. B cells expressing 'TOP1cc-enhanced ATAs' responded strongly to stimulation with TOP1-DNA complexes, whereas additive effects were not observed for B cells expressing 'regular' ATAs. CONCLUSIONS: The differential recognition of TOP1 upon DNA binding by ATAs demonstrates heterogeneity in the ATA B cell response, possibly impacting disease-relevant processes in severe SSc.
引用
- Neppelenbroek S, Wortel CM, van Rijswijck DMH, et al. Topoisomerase 1-DNA complexes are preferentially recognised by a subset of anti-topoisomerase 1 autoantibodies and their corresponding B cell receptors in systemic sclerosis. Ann Rheum Dis. 2026. PMID: 41968004. doi:10.1016/j.ard.2026.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。